Skip to content

Neural Activations During Imaginal Exposure in Individuals Fearful of Spiders

Neural Activations During Imaginal Exposure in Individuals Fearful of Spiders

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03969160
Enrollment
30
Registered
2019-05-31
Start date
2017-11-11
Completion date
2018-02-22
Last updated
2019-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Individuals With Fear of Spiders

Keywords

Imaginal exposure, brain imaging, mental imagery

Brief summary

This study explores the brain basis of imaginal exposure, a widely used psychological treatment technique. Specifically, this study uses functional magnetic resonance imaging to examine brain areas activated during imaginal exposure, in individuals fearful of spiders. Physiological responses and subjective fear experienced during imaginal exposure are also assessed. The primary aim of this study is to explore differences in neural activity during exposure to phobic, compared to neutral, mental imagery. The study will focus primarily on exploratory whole brain analyses, but will also include regions of interest analyses on brain areas previously associated with imaginal exposure. The experimental procedure consists of repeated exposure to mental imagery, i.e. imagery of short durations, including either highly emotion-provoking or neutral content, prompted by verbal instructions. A secondary aim is to explore the effects of repeated exposure to mental imagery, used during the experimental procedure, on subjective fear and physiological responses.

Detailed description

Results will elucidate if neural activity to phobic imagery differs from activity associated with the production of mental imagery per se. Findings will also increase our general understanding of the neural basis of imaginal exposure treatments.

Interventions

Imaginal exposure to mental imagery of phobic and neutral stimuli

Sponsors

Uppsala University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Significant fear of spiders

Exclusion criteria

* Current psychiatric disorder other than spider phobia * Substance abuse * Neurological disease * Psychological treatment or psychotropic medication within six months * Magnetic resonance imaging contradiction

Design outcomes

Primary

MeasureTime frameDescription
Blood oxygen level dependent contrast (BOLD-signal)Day 1BOLD-signal is assessed using functional magnetic resonance imaging.
Physiological response during exposure to mental imageryDay 1Skin-conductance responses are used as a measure of physiological response.

Secondary

MeasureTime frameDescription
Ratings of subjective fear experienced during exposure to mental imageryDay 1Scale: 0-100; no fear at all - extreme fear. Fear ratings are completed immediately after the imaginal exposure experimental procedure
Spielberger State-Trait Anxiety Inventory (STAI-S)Day 1STAI-S is a self-rated questionnaire included to assess state-anxiety experienced during exposure. High scores indicate high levels of state anxiety (range, total score: 20 - 80).
Differences in ratings of subjective fear during exposure to mental imagery, during day 1 compared to the follow-up session.Difference between day 1 and the follow-up session (one week after day 1)Scale: 0-100; no fear at all - extreme fear.
Vividness of mental imageryDay 1Vividness of mental imagery of phobic stimuli (scale: 1-5; no image at all - image as clear and vivid as real life).
Differences in vividness of mental imagery, during day 1 compared to the follow-up session.Difference between day 1 and the follow-up session (one week after day 1)Vividness of imagery of phobic stimuli (scale: 1-5; no image at all - image as clear and vivid as real life).
Difficulties in emotion regulation scale (DERS)Day 1DERS is a self-rated questionnaire, included to explore potential relations between imaginal exposure and difficulties in emotion regulation. High scores indicate more difficulties in emotion regulation (range, total score: 36 - 180)
Physiological response during exposure to mental imageryFollow-up (one week after day 1)Skin-conductance responses are used as a measure of physiological response.
Differences in physiological response during exposure to mental imagery, during day 1 compared to the follow-up session.Difference between day 1 and the follow-up session (one week after day 1)Skin-conductance responses are used as a measure of physiological response.
Ratings of subjective fear participants' expect to experience during exposure to mental imageryDay 1Scale: 0-100; no fear at all - extreme fear.

Other

MeasureTime frameDescription
Demand questionsDay 1Two questions asking participants' to appreciate the emotional impact of producing mental imagery versus focusing on the verbal aspects of phobic situations used in the experimental procedure. This measure is included as a manipulation check.
The Plymouth Sensory Imagery Questionnaire (Psi-Q)Day 1The Psi-Q is a self-rated measure of vividness of imagery across different sensory modalities. Higher scores indicate higher levels of vividness (range, total score 0 - 70).
Spider Phobia Questionnaire (SPQ)RecruitmentSPQ is a self-rated questionnaire assessing fear of spiders. A high score in SPQ (\>19) is required for inclusion in the study.
Spielberger State-Trait Anxiety Inventory (STAI-T)Day 1STAI-T is a self-rated questionnaire assessing trait anxiety and is included to describe the sample in terms of anxiety proneness. High scores indicate higher levels of trait anxiety (range, total score: 20 - 80)
Number of intrusive mental imagery of phobic stimuli7 days, starting on day 1.Number of intrusive mental images of phobic stimuli recorded by participants in a diary, daily (morning, afternoon, evening and night) for 7 days. This measure is included as a manipulation check.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026